Open AccessHereditary angioedema: experience of substitution therapy with a C1 esterase inhibitor in the Sverdlovsk region
Author(s) -
E K Beltyukov,
S. S. Vedenskaya,
I.S. Skorokhodov,
В. В. Наумова,
M.V. Beltyukova,
M L Karakina
Publication year - 2019
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja1211
Subject(s) - hereditary angioedema , christian ministry , angioedema , bradykinin , medicine , drug , pharmacology , dermatology , receptor , political science , law
Hereditary angioedema (HAO) is rare disease, however, it's lifethreatening localization can be fatal. Antifibrinolytics and attenuated androgens used for the prevention of HAO attacks have side effects, which limit their use. The bradykinin B2 receptor antagonist, Icatybant is an effective but shortacting dmedication. The human C1 esterase inhibitor (berinert) is safe and effective for the prevention and relief of angioedema of lifethreatening localization, including in pregnant women. The management of patients with HAO is regulated by national guidelines, and the use of a human C1 esterase inhibitor is recommended by instruction of the drug and by the Ministry of Health of the Sverdlovsk region. Patients with HAO should be provided with patient’s passport and fill a diary of symptoms monitoring of HAO.